LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 937 | 5578 | 0.1680 | -0.5293 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1016 | 5578 | 0.1822 | -0.5031 |
| SK-BR-3 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 2543 | 5645 | 5578 | 1.0119 | 1.0219 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 702 | 5578 | 0.1260 | -0.6065 |
| SK-BR-3 | GSK 690693 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 4505 | 5578 | 0.8075 | 0.6463 |
| SK-BR-3 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1353 | 5578 | 0.2426 | -0.3921 |
| SK-BR-3 | HG-5-113-01 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1703 | 5578 | 0.3053 | -0.2769 |
| SK-BR-3 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 2531 | 5578 | 0.4538 | -0.0040 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 5265 | 5578 | 0.9438 | 0.8968 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1607 | 5578 | 0.2881 | -0.3085 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1552 | 5578 | 0.2782 | -0.3267 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 2824 | 5578 | 0.5062 | 0.0924 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 768 | 5578 | 0.1378 | -0.5847 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 3086 | 5578 | 0.5533 | 0.1790 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 4150 | 5578 | 0.7440 | 0.5294 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 2543 | 494 | 5578 | 0.0887 | -0.6750 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 2543 | 295 | 5578 | 0.0529 | -0.7408 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 2333 | 5578 | 0.4182 | -0.0693 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1363 | 5578 | 0.2444 | -0.3888 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2836 | 5578 | 0.5084 | 0.0964 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 3807 | 5578 | 0.6824 | 0.4163 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 3417 | 5578 | 0.6126 | 0.2880 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2257 | 5578 | 0.4046 | -0.0943 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 2123 | 5578 | 0.3806 | -0.1385 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 3847 | 5578 | 0.6896 | 0.4295 |